Avenacy Launches Generic Diphenhydramine Injectable, Marking 26th Product Since 2023 Inception
核心洞察
Avenacy (搜索) announced the U.S. launch of Diphenhydramine Hydrochloride Injection, USP, a generic equivalent of BENADRYL® for treating allergic reactions, motion sickness, and parkinsonism when oral therapy is not feasible.
The injectable product represents the company's 26th launch since its October 2023 inception and first product introduction of 2026, highlighting rapid portfolio expansion.
U.S. sales of diphenhydramine injection reached approximately $17.2 million for the twelve months ending December 2025, indicating significant market opportunity.
Specialty pharmaceutical company Avenacy (搜索) has launched Diphenhydramine Hydrochloride Injection, USP in the United States, marking the company's 26th product offering since its inception in October 2023. The FDA-approved generic equivalent of BENADRYL® addresses critical treatment needs for allergic reactions, motion sickness, and certain cases of parkinsonism when oral therapy is not feasible.
Product Specifications and Market Impact
The injectable formulation contains 50 mg per 1 mL and is packaged as cartons of 25 single-dose vials. According to IQVIA data, U.S. sales of Diphenhydramine Hydrochloride Injection, USP totaled approximately $17.2 million for the twelve months ending December 2025, representing a substantial market opportunity for the emerging pharmaceutical company.
"Since launching Avenacy (搜索) in October 2023, we have remained focused on building a reliable portfolio of essential injectable medications that hospitals depend on every day to deliver consistent care to patients," said Jeff Yordon, Co-Founder and CEO of Avenacy. "The addition of Diphenhydramine Hydrochloride Injection marks our 26th product offering and our first launch of 2026. We look forward to continuing to strengthen our portfolio with critical injectable medicines."
Clinical Applications and Safety Profile
The injection is indicated for multiple therapeutic uses in both adult and pediatric patients when oral administration is impractical. As an antihistaminic agent, it treats allergic reactions to blood or plasma and serves as an adjunct in anaphylaxis after acute symptoms have been controlled with epinephrine and other standard measures. The product also addresses motion sickness and provides antiparkinsonism effects when oral therapy is impossible or contraindicated.
However, the medication carries important safety restrictions. It is contraindicated in neonates and premature infants, as well as nursing mothers due to higher antihistamine risks in infants. The drug should not be used as a local anesthetic due to the risk of local necrosis, and it is contraindicated in patients with hypersensitivity to diphenhydramine hydrochloride or similar antihistamines.
Manufacturing and Distribution Strategy
Avenacy (搜索) will begin shipping the product to wholesale partners this week, supported by a global network of development and contract manufacturing partners that have undergone successful FDA inspections based on current Good Manufacturing Practice (cGMP) standards. The company emphasizes its commitment to patient safety through highly differentiated packaging and labeling designed to support accurate medication selection.
The rapid expansion of Avenacy (搜索)'s portfolio demonstrates the company's strategic focus on addressing supply chain needs for critical injectable medications used across various medically supervised settings, from acute care hospitals to outpatient clinics and physician offices.